Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The efficacy of GLP-1s has made them a breakthrough not only in managing obesity and diabetes, but also in their potential to ...

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...

After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...

Still, gross spending on the drugs increased by more than 500% from 2019 to 2023, according to the health policy research ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...